Cargando…

Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine

There are limited reports concerning the levels of antibodies in IgG subclasses and the avidity of IgG, which is the functional strength with which an antibody binds to an antigen in serum samples obtained at different times after infection or vaccination. This study investigated the kinetics of ant...

Descripción completa

Detalles Bibliográficos
Autores principales: Rastawicki, Waldemar, Gierczyński, Rafał, Zasada, Aleksandra Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146688/
https://www.ncbi.nlm.nih.gov/pubmed/37112950
http://dx.doi.org/10.3390/v15040970
_version_ 1785034638631108608
author Rastawicki, Waldemar
Gierczyński, Rafał
Zasada, Aleksandra Anna
author_facet Rastawicki, Waldemar
Gierczyński, Rafał
Zasada, Aleksandra Anna
author_sort Rastawicki, Waldemar
collection PubMed
description There are limited reports concerning the levels of antibodies in IgG subclasses and the avidity of IgG, which is the functional strength with which an antibody binds to an antigen in serum samples obtained at different times after infection or vaccination. This study investigated the kinetics of antibody avidity and the IgG antibody response within IgG1-IgG4 subclasses in individuals vaccinated with the BNT162B2 mRNA vaccine and in COVID-19 patients. Serum samples were collected from individuals vaccinated with three doses of the BNT162B2 (Comirnaty, Pfizer/BioNTech) vaccine and from unvaccinated COVID-19 patients. This study revealed that IgG1 was a dominating subclass of IgG both in COVID-19 patients and in vaccinated individuals. The level of IgG4 and IgG avidity significantly increased 7 months after the first two doses of the vaccine and then again after the third dose. IgG2 and IgG3 levels were low in most individuals. Investigating IgG avidity and the dynamics of IgG subclasses is essential for understanding the mechanisms of protection against viral infections, including COVID-19, especially in the context of immunization with innovative mRNA vaccines and the possible future development and application of mRNA technology.
format Online
Article
Text
id pubmed-10146688
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101466882023-04-29 Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine Rastawicki, Waldemar Gierczyński, Rafał Zasada, Aleksandra Anna Viruses Communication There are limited reports concerning the levels of antibodies in IgG subclasses and the avidity of IgG, which is the functional strength with which an antibody binds to an antigen in serum samples obtained at different times after infection or vaccination. This study investigated the kinetics of antibody avidity and the IgG antibody response within IgG1-IgG4 subclasses in individuals vaccinated with the BNT162B2 mRNA vaccine and in COVID-19 patients. Serum samples were collected from individuals vaccinated with three doses of the BNT162B2 (Comirnaty, Pfizer/BioNTech) vaccine and from unvaccinated COVID-19 patients. This study revealed that IgG1 was a dominating subclass of IgG both in COVID-19 patients and in vaccinated individuals. The level of IgG4 and IgG avidity significantly increased 7 months after the first two doses of the vaccine and then again after the third dose. IgG2 and IgG3 levels were low in most individuals. Investigating IgG avidity and the dynamics of IgG subclasses is essential for understanding the mechanisms of protection against viral infections, including COVID-19, especially in the context of immunization with innovative mRNA vaccines and the possible future development and application of mRNA technology. MDPI 2023-04-14 /pmc/articles/PMC10146688/ /pubmed/37112950 http://dx.doi.org/10.3390/v15040970 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Communication
Rastawicki, Waldemar
Gierczyński, Rafał
Zasada, Aleksandra Anna
Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
title Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
title_full Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
title_fullStr Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
title_full_unstemmed Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
title_short Comparison of Kinetics of Antibody Avidity and IgG Subclasses’ Response in Patients with COVID-19 and Healthy Individuals Vaccinated with the BNT162B2 (Comirnaty, Pfizer/BioNTech) mRNA Vaccine
title_sort comparison of kinetics of antibody avidity and igg subclasses’ response in patients with covid-19 and healthy individuals vaccinated with the bnt162b2 (comirnaty, pfizer/biontech) mrna vaccine
topic Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10146688/
https://www.ncbi.nlm.nih.gov/pubmed/37112950
http://dx.doi.org/10.3390/v15040970
work_keys_str_mv AT rastawickiwaldemar comparisonofkineticsofantibodyavidityandiggsubclassesresponseinpatientswithcovid19andhealthyindividualsvaccinatedwiththebnt162b2comirnatypfizerbiontechmrnavaccine
AT gierczynskirafał comparisonofkineticsofantibodyavidityandiggsubclassesresponseinpatientswithcovid19andhealthyindividualsvaccinatedwiththebnt162b2comirnatypfizerbiontechmrnavaccine
AT zasadaaleksandraanna comparisonofkineticsofantibodyavidityandiggsubclassesresponseinpatientswithcovid19andhealthyindividualsvaccinatedwiththebnt162b2comirnatypfizerbiontechmrnavaccine